Cargando…
A randomized, double-blind, single-dose study (LAVENDER) to assess the safety, tolerability, pharmacokinetics, and immunogenicity of a combined infusion of ABP 980 and pertuzumab in healthy subjects
PURPOSE: ABP 980 (KANJINTI(™)) is a biosimilar to reference product HERCEPTIN(®) (trastuzumab RP). The goal of this study was to characterize the safety, tolerability, and immunogenicity of ABP 980 plus pertuzumab (PERJETA(®)) when co-administered in a single infusion bag in healthy subjects. METHOD...
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer Berlin Heidelberg
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8484235/ https://www.ncbi.nlm.nih.gov/pubmed/34355250 http://dx.doi.org/10.1007/s00280-021-04334-x |